aim immunoTech CEO Equels buys $5,068 in common stock

Thomas K. Equels, CEO and President of AIM ImmunoTech Inc., purchased 31,675 shares of the company's common stock on October 23, 2026. The transaction amounted to $5,068, with each share bought for $0.16. This investment occurred as the stock was trading near its 52-week low of $0.15, indicating a 94% decline in value over the past year.

According to InvestingPro analysis, the stock appears to be undervalued, being listed among the platform's most undervalued stocks. Following this acquisition, Mr. Equels now directly owns 189,747 shares of AIM ImmunoTech common stock. Additionally, AIM ImmunoTech recently announced a $1.5 million manufacturing agreement with Sterling Pharma Solutions.

The agreement pertains to producing additional batches of the polynucleotide drug substances PolyI and Poly C12U for AIM ImmunoTech's drug product, Ampligen. This collaboration, based on prior arrangements from 2022, will take place at Sterling Pharma's facility in Dudley, UK. Furthermore, AIM ImmunoTech's CEO published an article in Breaking Defense discussing the potential of Ampligen as a broad-spectrum antiviral therapeutic, particularly for Ebola virus disease and COVID-19.

However, the article emphasizes that preclinical findings do not confirm FDA approval or clinical efficacy. AIM ImmunoTech has clarified that the forward-looking statements regarding future clinical trials and regulatory submissions do not guarantee outcomes. These developments highlight AIM ImmunoTech's ongoing commitment to advancing its antiviral therapeutic strategies.